But the most striking thing, for a CT advocate, was the FDA’s
discipline around ethics. Applicants to FDA committees complete a thick stack
of documentation to ensure no conflicts of interest. The only voting members of
the committee are independent clinical/academic experts, agency experts and
consumer representatives. This may sound strange to anyone in CT policymaking,
but they are very strict that drug companies do not vote on or influence the
regulations they operate under. Weighing the best interests of consumers was
the only priority – for everyone at the meeting. In CT we routinely have industries
at the table, and people with financial
interests in those industries, usually dominating the membership. In CT, industries
are making decisions about what standards they have to reach, what they can
charge, and how they will be monitored (if at all). Consumers and advocates
have to fight our way into the process -- preferably at the table, but if
necessary by other means – and we are punished for it. The entire day I never
heard about how our or FDA’s decisions would affect jobs or stock prices. It
just never came up – protecting people and saving lives is the only priority.
Tuesday, April 1, 2014
My first FDA Advisory Committee meeting – refreshing change from CT
I was recently appointed as a consumer representative to the
FDA’s
Anti-Infective Drug Advisory Committee and yesterday was my first meeting. It
was a bit intimidating to open the Wall
Street Journal that morning to see an article about our meeting. It was
fascinating – I learned more new things yesterday than I did all last year. The
committee advises the FDA about new antibiotics with a deep dive into science
and clinical trials on effectiveness and safety. Drug resistant bacterial
infections affect 2 million Americans each year, killing 23,000, according to the
CDC. There are 45
new antibiotics in the pipeline and yesterday we considered two of them. We
heard from a small army of very impressive, dedicated, extremely well prepared
experts, from both the FDA and the applicant drug companies, who answered every
question the committee posed. The room was packed. We heard very moving public
comment from families and patients affected by MRSA and from researchers
concerned about protecting the public.